 |
|||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||
|
Strong VC-trio Invest in PharmaSurgics Wound Healing Product Gothenburg 2008-05-26 PharmaSurgics AB has received SEK 17 million to complete the preclinical development of their candidate drug (PXL01). The primary indication for PXL01 is the prevention of post-surgical adhesions and the clinical documentation will start in Q1 2009. The investment round led by Karolinska Development (KD) also included Östersjöstiftelsen and Midroc New Technology.
|
||||||||||||||||||||||||||||||||||||||||||||
Press release